Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation

Transplantation

Volumn 84, Issue 10, 2007, Pages 1215-1219

  Ashton Chess, Joanna ^b   Giral, Magali ^b   Brouard, Sophie ^a   Soulillou, Jean Paul ^a  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

Immunosuppression withdrawal; Kidney transplantation; Spontaneous operational tolerance

Indexed keywords

ABATACEPT; ALEMTUZUMAB; IMMUNOSUPPRESSIVE AGENT; STEROID;

DRUG WITHDRAWAL; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSPLANT TOLERANCE; UNSPECIFIED SIDE EFFECT; ALLOTRANSPLANTATION; DRUG ADMINISTRATION; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; TIME; TRANSPLANTATION TOLERANCE;

DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MONITORING, IMMUNOLOGIC; TIME FACTORS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 38449100017     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000290683.54937.1b     Document Type: Review

References (47)

1. Billingham RE, Brent L, Medawar PB. Activity acquired tolerance of foreign cells. Nature 1953; 172: 603.
2. Koshiba T, Kitade H, Van Damme B, et al. Regulatory cell-mediated tolerance does not protect against chronic rejection. Transplantation 2003; 76: 588.
3. Lair D, Degauque N, Miqueu P, et al. Functional compartmentalization following induction of long-term graft survival with pregraft donor-specific transfusion. Am J Transplant 2007; 7: 538.
4. Guillot C, Guillonneau C, Mathieu P, et al. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 2002; 168: 1600.
5. Xu Q, Lee J, Jankowska-Gan E, et al. Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol 2007; 178: 3983.
6. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6: 2121.
7. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
8. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80: 1051.
9. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
10. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954.
11. Sellers MT, Deierhoi MH, Curtis JJ, et al. Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up. Transplantation 2001; 71: 1681.
12. Jacobsen N, Taaning E, Ladefoged J, Kristensen JK, Pedersen FK. Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet 1994; 343: 800.
13. Helg C, Chapuis B, Bolle JF, et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation 1994; 58: 1420.
14. Butcher JA, Hariharan S, Adams MB, Johnson CP, Roza AM, Cohen EP. Renal transplantation for end-stage renal disease following bone marrow transplantation: A report of six cases, with and without immunosuppression. Clin Transplant 1999; 13: 330.
15. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3: 51.
16. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926.
17. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449.
18. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6: 1774.
19. Zoller KM, Cho SI, Cohen JJ, Harrington JT. Cessation of immunosuppressive therapy after successful transplantation: A national survey. Kidney Int 1980; 18: 110.
20. Uehling DT, Hussey JL, Weinstein AB, Wank R, Bach FH. Cessation of immunosuppression after renal transplantation. Surgery 1976; 79: 278.
21. Cai J, Lee J, Jankowska-Gan E, et al. Minor H antigen HA-1-specific regulator and effector CD8 T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199: 1017.
22. Burlingham WJ, Grailer AP, Fechner JH Jr, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995; 59: 1147.
23. Christensen LL, Grunnet N, Rudiger N, Moller B, Birkeland SA. Indications of immunological tolerance in kidney transplantation. Tissue Antigens 1998; 51: 637.
24. Fischer T, Schobel H, Barenbrock M. Specific immune tolerance during pregnancy after renal transplantation. Eur J Obstet Gynecol Reprod Biol 1996; 70: 217.
25. Roussey-Kesler G, Giral M, Moreau M, Subra JF, Lengendre C, Noel C, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736.
26. Ballet C, Roussey-Kesler G, Aubin JT, et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 2006; 6: 2796.
27. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5: 330.
28. Baeten D, Louis S, Braud C, et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006; 17: 294.
29. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398.
30. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448.
31. Degauque N, Lair D, Dupont A, et al. Dominant tolerance to kidney allografts induced by anti-donor MHC class II antibodies: Cooperation between T and non-T CD103+ cells. J Immunol 2006; 176: 3915.
32. Haspot F, Seveno C, Dugast AS, et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005; 5: 2339.
33. Guillonneau C, Aubry V, Renaudin K, et al. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. Transplantation 2005; 80: 546.
34. Chiffoleau E, Beriou G, Dutartre P, Usal C, Soulillou JP, Cuturi MC. Induction of donor-specific allograft tolerance by short-term treatment with LF15-0195 after transplantation. Evidence for a direct effect on T-cell differentiation. Am J Transplant 2002; 2: 745.
35. Beriou G, Peche H, Guillonneau C, Merieau E, Cuturi MC. Donorspecific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation 2005; 79: 969.
36. Chiffoleau E, Beriou G, Dutartre P, Usal C, Soulillou JP, Cuturi MC. Role for thymic and splenic regulatory CD4+T cells induced by donor dendritic cells in allograft tolerance by LF15-0195 treatment. J Immunol 2002; 168: 5058.
37. Degauque N, Lair D, Braudeau C, et al. Development of CD25+ regulatory T cells following heart transplantation: Evidence for transfer of long-term survival. Eur J Immunol 2007; 37: 147.
38. Guillonneau C, Hill M, Hubert FX, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 1096.
39. Braud C, Baeten D, Giral M, et al. Peripheral blood gene expression of chronic rejection in renal allograft transplantatio. Transplantation 2006; 82(1 Suppl 2): 401.
40. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
41. Braudeau C, Racape M, Giral M, et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007; 30: 845.
42. Kawai T, Suthanthiran M, Sharma V, et al. Intragraft RNA expression of FOXP3 versus proinflammatory cytokines in tolerant recipients of HLA mismatched renal allografts. American Transplant Congress 2007; Abstract 1717.
43. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
44. Veronese F, Rotman S, Smith RN, et al. Pathological and clinical correlates of FOXP3+cells in renal allografts during acute rejection. Am J Transplant 2007; 7: 914.
45. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145.
46. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003; 349: 2288.
47. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.